ALDX Q1 2023 Earnings — Aldeyra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ALDXAldeyra Therapeutics, Inc.

$318M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$17M

Net Income

-$16M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$168M

Total Liabilities

$31M

Stockholders' Equity

$137M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$17M	-$16M	-1.9%
Net Income	-$16M	-$17M	+7.0%